---
stable_id: R-HSA-9686790
display_name: ER-alpha glucosidases bind ER-alpha glucosidase inhibitors
species: Homo sapiens
summary: Inhibition of host cellular functions required for viral replication is considered
  another host-targeting antiviral strategy. Extensive pharmacological studies have
  validated ER glucosidases as valuable host antiviral targets against many enveloped
  viruses (Chang et al. 2013). Most known ER glucosidase inhibitors are imino sugars
  like 1-deoxynojirimycin (DNJ) and castanopermine (CAST) derivatives (Taylor et al.
  1994).<br><br>It is generally believed that inhibition of ER glucosidase I and/or
  II prevents the removal of the terminal glucose moieties on N-linked glycans and
  results in misfolding and retention of glycoproteins in the ER and ultimate degradation
  via the ER-associated degradation (ERAD) pathway (Simsek et al. 2005, Alonzi et
  al. 2013).  As a consequence of the abnormal trafficking and degradation of viral
  glycoproteins, virion assembly and secretion are inhibited (Chang et al. 2009, Taylor
  et al. 1998).<br><br>Long-term suppression of ER glucosidases I and/or II with more
  potent inhibitors may cause significant side effects, particularly in nerve and
  immune systems (Sadat et al. 2014).
---

# ER-alpha glucosidases bind ER-alpha glucosidase inhibitors
**Reactome ID:** [R-HSA-9686790](https://reactome.org/content/detail/R-HSA-9686790)
**Species:** Homo sapiens

## Summary

Inhibition of host cellular functions required for viral replication is considered another host-targeting antiviral strategy. Extensive pharmacological studies have validated ER glucosidases as valuable host antiviral targets against many enveloped viruses (Chang et al. 2013). Most known ER glucosidase inhibitors are imino sugars like 1-deoxynojirimycin (DNJ) and castanopermine (CAST) derivatives (Taylor et al. 1994).<br><br>It is generally believed that inhibition of ER glucosidase I and/or II prevents the removal of the terminal glucose moieties on N-linked glycans and results in misfolding and retention of glycoproteins in the ER and ultimate degradation via the ER-associated degradation (ERAD) pathway (Simsek et al. 2005, Alonzi et al. 2013).  As a consequence of the abnormal trafficking and degradation of viral glycoproteins, virion assembly and secretion are inhibited (Chang et al. 2009, Taylor et al. 1998).<br><br>Long-term suppression of ER glucosidases I and/or II with more potent inhibitors may cause significant side effects, particularly in nerve and immune systems (Sadat et al. 2014).
